Infantile-onset Pompe disease: Diagnosis and management

Area of Science:

• Genetics
• Metabolic Disorders
• Neuromuscular Diseases

Background:

• Pompe disease, or glycogenosis type II, is a rare, autosomal recessive, progressive genetic disorder.
• It stems from a deficiency in the enzyme alpha-glucosidase, leading to glycogen accumulation.
• The disease presents in infantile-onset (severe hypotonia, cardiac issues) and late-onset forms (motor involvement).

Purpose of the Study:

• To provide an updated overview of clinical and diagnostic findings in Pompe disease.
• To highlight the importance of early management, particularly enzyme replacement therapy (ERT).
• To review current treatment benefits, adverse effects, and emerging therapeutic research.

Main Methods:

• Literature review of clinical and diagnostic findings.
• Analysis of current treatment options, including enzyme replacement therapy.
• Exploration of novel therapeutic research avenues.

Main Results:

• Early diagnosis and intervention with ERT can enhance patient survival and quality of life.
• Available treatments offer benefits but also carry potential adverse effects.
• Ongoing research is exploring new therapeutic strategies for Pompe disease.

Conclusions:

• Timely diagnosis and initiation of enzyme replacement therapy are crucial for improving outcomes in Pompe disease.
• A comprehensive understanding of treatment benefits and risks is essential for patient management.
• Continued research into novel therapies holds promise for advancing Pompe disease treatment.